AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 15055-

  Lukashchuk, Vera ^a   Lewis, Katherine E ^a   Coldicott, Ian ^a   Grierson, Andrew J ^a   Azzouz, Mimoun ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; HB9 PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; PROTEIN; SYNAPSIN I; UNCLASSIFIED DRUG; ADENO ASSOCIATED VIRUS VECTOR; BETA ACTIN; CYTOMEGALOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; HERPESVIRUS VECTOR; TRANSCRIPTION FACTOR;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CERVICAL SPINAL CORD; CISTERNA MAGNA; CONTROLLED STUDY; EMBRYO; ENHANCER REGION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GLIA; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNEURON; LUMBAR SPINAL CORD; MOTONEURON; MOTOR CORTEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PURKINJE CELL; SELF COMPLEMENTARY ADENO ASSOCIATED VIRUS SEROTYPE 9; SPINAL CORD CELL CULTURE; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS 9; ANIMAL CELL; ANIMAL EXPERIMENT; BLOOD BRAIN BARRIER; CAG REPEAT; CENTRAL NERVOUS TISSUE; CEREBROSPINAL FLUID; CHICKEN; COMPARATIVE STUDY; CYTOMEGALOVIRUS; IN VIVO GENE TRANSFER; NERVE CELL; NEWBORN;

EID: 85009778594     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.55     Document Type: Article

References (40)

1. 1 Dayton, RD, Wang, DB, Klein, RL, The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 12 (2012), 757–766.
2. 2 Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM, Kaspar, BK, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27 (2009), 59–65.
3. 3 Foust, KD, Salazar, DL, Likhite, S, Ferraiuolo, L, Ditsworth, D, Ilieva, H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21 (2013), 2148–2159.
4. 4 Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28 (2010), 271–274.
5. 5 Valori, CF, Ning, K, Wyles, M, Mead, RJ, Grierson, AJ, Shaw, PJ, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med, 2, 2010, 35ra42.
6. 6 Fu, H, Muenzer, J, Samulski, RJ, Breese, G, Sifford, J, Zeng, X, et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8 (2003), 911–917.
7. 7 Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78 (2004), 6381–6388.
8. 8 Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR, Samulski, RJ, Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19 (2011), 1058–1069.
9. 9 Inagaki, K, Fuess, S, Storm, TA, Gibson, GA, Mctiernan, CF, Kay, MA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14 (2006), 45–53.
10. 10 Gholizadeh, S, Tharmalingam, S, Macaldaz, ME, Hampson, DR, Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. Hum Gene Ther Methods 24 (2013), 205–213.
11. 11 Ayers, JI, Fromholt, S, Sinyavskaya, O, Siemienski, Z, Rosario, AM, Li, A, et al. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther 23 (2015), 53–62.
12. 12 Bucher, T, Colle, MA, Wakeling, E, Dubreil, L, Fyfe, J, Briot-Nivard, D, et al. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther 24 (2013), 670–682.
13. 13 Gray, SJ, Nagabhushan Kalburgi, S, McCown, TJ, Jude Samulski, R, Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20 (2013), 450–459.
14. 14 Samaranch, L, Salegio, EA, San Sebastian, W, Kells, AP, Bringas, JR, Forsayeth, J, et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 24 (2013), 526–532.
15. 15 Samaranch, L, Salegio, EA, San Sebastian, W, Kells, AP, Foust, KD, Bringas, JR, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 23 (2012), 382–389.
16. 16 Hinderer, C, Bell, P, Vite, CH, Louboutin, JP, Grant, R, Bote, E, et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev, 1, 2014, 14051.
17. 17 McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P, Samulski, RJ, Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10 (2003), 2112–2118.
18. 18 Gray, SJ, Foti, SB, Schwartz, JW, Bachaboina, L, Taylor-Blake, B, Coleman, J, et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22 (2011), 1143–1153.
19. 19 Zincarelli, C, Soltys, S, Rengo, G, Rabinowitz, JE, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16 (2008), 1073–1080.
20. 20 McLean, JR, Smith, GA, Rocha, EM, Hayes, MA, Beagan, JA, Hallett, PJ, et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett 576 (2014), 73–78.
21. 21 Nathanson, JL, Yanagawa, Y, Obata, K, Callaway, EM, Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience 161 (2009), 441–450.
22. 22 Kügler, S, Lingor, P, Schöll, U, Zolotukhin, S, Bähr, M, Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311 (2003), 89–95.
23. 23 Kügler, S, Meyn, L, Holzmüller, H, Gerhardt, E, Isenmann, S, Schulz, JB, et al. Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol Cell Neurosci 17 (2001), 78–96.
24. 24 Garg, SK, Lioy, DT, Cheval, H, McGann, JC, Bissonnette, JM, Murtha, MJ, et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci 33 (2013), 13612–13620.
25. 25 Hioki, H, Kameda, H, Nakamura, H, Okunomiya, T, Ohira, K, Nakamura, K, et al. Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters. Gene Ther 14 (2007), 872–882.
26. 26 Peviani, M, Kurosaki, M, Terao, M, Lidonnici, D, Gensano, F, Battaglia, E, et al. Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. J Neurosci Methods 205 (2012), 139–147.
27. 27 Lee, SK, Jurata, LW, Funahashi, J, Ruiz, EC, Pfaff, SL, Analysis of embryonic motoneuron gene regulation: derepression of general activators function in concert with enhancer factors. Development 131 (2004), 3295–3306.
28. 28 Arber, S, Han, B, Mendelsohn, M, Smith, M, Jessell, TM, Sockanathan, S, Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. Neuron 23 (1999), 659–674.
29. 29 Wilson, JM, Hartley, R, Maxwell, DJ, Todd, AJ, Lieberam, I, Kaltschmidt, JA, et al. Conditional rhythmicity of ventral spinal interneurons defined by expression of the Hb9 homeodomain protein. J Neurosci 25 (2005), 5710–5719.
30. 30 Nakano, T, Windrem, M, Zappavigna, V, Goldman, SA, Identification of a conserved 125 base-pair Hb9 enhancer that specifies gene expression to spinal motor neurons. Dev Biol 283 (2005), 474–485.
31. 31 Schuster, DJ, Dykstra, JA, Riedl, MS, Kitto, KF, Belur, LR, Mclvor, RS, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat, 8, 2014, 42.
32. 32 Haidet-Phillips, AM, Hester, ME, Miranda, CJ, Meyer, K, Braun, L, Frakes, A, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29 (2011), 824–828.
33. 33 Rindt, H, Feng, Z, Mazzasette, C, Glascock, JJ, Valdivia, D, Pyles, N, et al. Astrocytes influence the severity of spinal muscular atrophy. Hum Mol Genet 24 (2015), 4094–4102.
34. 34 McGivern, JV, Patitucci, TN, Nord, JA, Barabas, ME, Stucky, CL, Ebert, AD, Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 61 (2013), 1418–1428.
35. 35 Peters, O, Schipke, CG, Philipps, A, Haas, B, Pannasch, U, Wang, LP, et al. Astrocyte function is modified by Alzheimer's disease-like pathology in aged mice. J Alzheimers Dis 18 (2009), 177–189.
36. 36 Karumbayaram, S, Novitch, BG, Patterson, M, Umbach, JA, Richter, L, Lindgren, A, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 27 (2009), 806–811.
37. 37 Singh Roy, N, Nakano, T, Xuing, L, Kang, J, Nedergaard, M, Goldman, SA, Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells. Exp Neurol 196 (2005), 224–234.
38. 38 Mingozzi, F, High, KA, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12 (2011), 341–355.
39. 39 Niwa, H, Yamamura, K, Miyazaki, J, Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991), 193–199.
40. 40 Lock, M, Alvira, M, Vandenberghe, LH, Samanta, A, Toelen, J, Debyser, Z, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 21 (2010), 1259–1271.